We use cookies

Essential storage keeps the site working (sign-in, theme, this choice). We'd also like to load Google Analytics to understand, in aggregate, how the site is used — never your genetic data. See our Cookie Policy.

CYP2C19 rs72549307 (*8 Allele): Pharmacogenomic Impact

rs72549307
Pharmacogenomics
Limited evidenceGene: CYP2C19

The genetic variant rs72549307 is a rare single-nucleotide polymorphism within the CYP2C19 gene that defines the CYP2C19*8 loss-of-function allele. Carrying this non-functional variant reduces the body's capacity to metabolize key pharmaceuticals, including the antiplatelet prodrug clopidogrel and the antidepressant escitalopram. Because of its rarity in the general population, it has limited direct clinical trial representation and is classified alongside other non-functional star alleles by pharmacogenetic consortia.

What each genotype means

GenotypeWhat the research suggestsReading
TTYou carry two copies of the standard reference allele and do not possess the rare CYP2C19*8 loss-of-function variant. Your baseline CYP2C19 enzyme activity from this particular genomic position is unaffected, though other genetic variants must be analyzed to determine your overall metabolic phenotype. This is the common genotype found across all ancestral populations.Informational
CTYou carry one copy of the rare C allele defining the CYP2C19*8 loss-of-function variant alongside one standard allele. This genotype is associated with decreased overall CYP2C19 enzymatic capacity, typically categorizing you as an intermediate or poor metabolizer depending on your other CYP2C19 star alleles. You may process medications like clopidogrel and escitalopram less effectively than normal metabolizers.Higher attention
CCYou carry two copies of the rare CYP2C19*8 loss-of-function variant, an extraordinarily rare occurrence in the general population. This genotype predicts an absence of functional CYP2C19 enzyme activity, categorizing you as a poor metabolizer. This status significantly hinders the activation of clopidogrel and drastically reduces the clearance rate of escitalopram.Higher attention

What is rs72549307 and Where is It Located?

The single-nucleotide variant rs72549307 is located within the CYP2C19 gene on chromosome 10 at 10q23.33. At the molecular level, this variation represents a missense substitution known as c.358T>C, which results in the replacement of a tryptophan residue with an arginine at codon 120 (p.Trp120Arg). In pharmacogenomic nomenclature curated by the Pharmacogene Variation (PharmVar) Consortium, this specific single-nucleotide change characterizes the CYP2C19*8 allele. Structurally, the replacement of this conserved amino acid disrupts normal protein folding or catalytic integrity, resulting in a protein with absent or negligible enzymatic capability. Unlike widespread non-functional variants like CYP2C19*2 or *3, which represent splicing or premature stop mutations, *8 is an uncommon missense alteration that leads to a similar functional null phenotype.

The Role of the CYP2C19 Enzyme in Drug Metabolism

The CYP2C19 gene provides the biological instructions for synthesizing cytochrome P450 2C19, a vital membrane-bound enzyme anchored in the endoplasmic reticulum of liver hepatocytes. This enzyme acts as a catalyst in the phase I oxidative metabolism of roughly 10% of commonly prescribed therapeutic drugs. Its substrates include cardiovascular agents such as clopidogrel, selective serotonin reuptake inhibitors (SSRIs) such as escitalopram and citalopram, and proton pump inhibitors like omeprazole. The functional outcome of CYP2C19 activity depends on the drug: for prodrugs like clopidogrel, the enzyme is required to bioactivate the compound into its antiplatelet form. For active drugs like escitalopram, the enzyme plays a primary role in clearing and inactivating the compound, protecting against excessive drug accumulation.

Research Associations and Evidence Strength

Clinical consortia like the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB classify CYP2C19*8 as a definitive 'no function' allele. However, the direct clinical evidence base specifically tracking rs72549307 outcomes is categorized as limited. Because rs72549307 is rare, broad-scale randomized cardiovascular and psychiatric trials evaluate outcomes by pooling it into aggregate 'loss-of-function' (LOF) or 'poor metabolizer' cohorts alongside common alleles like *2. In carriers of two loss-of-function alleles, clopidogrel bioactivation is severely diminished, leading to reduced platelet inhibition and elevated risks of secondary ischemic events. Conversely, for escitalopram, reduced clearance elevates plasma drug concentrations, increasing the likelihood of adverse side effects. While the mechanistic null assignment is experimentally sound, variant-specific statistical power in isolated studies remains modest.

Population Frequency and Ancestry Patterns

The rs72549307 variant is an exceedingly rare allele on a global scale. In major genomic repositories such as the Genome Aggregation Database (gnomAD) and PharmVar population surveys, the minor allele frequency (MAF) consistently measures below 0.005 (<0.5%). The variant has been observed predominantly in European-descent cohorts at very low frequencies and is virtually undetectable or absent in East Asian, African, and Indigenous populations. Consequently, homozygous carriers (C/C) are extraordinarily rare in clinical genetics. The vast majority of individuals carrying this variant are heterozygous (C/T), inheriting one null *8 allele paired with a normal function allele (*1) or another loss-of-function allele (*2 or *3), placing them in the intermediate or poor metabolizer phenotype classes.

Clinical Implications and How to Use This Information

Understanding your rs72549307 status offers useful insight into how your liver handles certain medications, but genetic data alone should never dictate your medical care. Never initiate, discontinue, or alter dosages of any medication—including antiplatelet agents like clopidogrel or antidepressants like escitalopram—without explicit guidance from a prescribing physician or pharmacist. Clinicians assess comprehensive clinical factors, such as kidney function, age, body weight, concurrent drug therapies, and overall cardiovascular risk, alongside your genotype. If a clinical pharmacogenetic test identifies a CYP2C19*8 allele, professional guidelines from organizations like CPIC and the FDA provide actionable recommendations to select alternative antiplatelet therapies or modify SSRI dosing to ensure safety and effectiveness.

How common is this variant?

The rs72549307 (C) allele is an extremely rare null variant with a global minor allele frequency below 0.005 (<0.5%), detected primarily in individuals of European ancestry and rarely found in other global populations.

Frequently asked questions

Does carrying rs72549307 mean clopidogrel will not work for me?

Carrying rs72549307 reduces your liver's ability to convert clopidogrel into its active antiplatelet form. If paired with another non-functional allele, clopidogrel may be significantly less effective, raising your risk for blood clots; however, only your doctor can determine if an alternative medication is necessary.

How does rs72549307 affect antidepressants like escitalopram?

The CYP2C19 enzyme is responsible for clearing escitalopram from the bloodstream. Carrying this loss-of-function variant can cause escitalopram to clear more slowly, potentially leading to higher drug concentrations and a greater risk of adverse effects, requiring careful dose monitoring by your physician.

Is CYP2C19*8 tested on standard genetic health screens?

Many routine commercial genetic screens only test for the most common CYP2C19 variants (*2, *3, and *17). Because rs72549307 is rare, it is usually only captured on comprehensive clinical pharmacogenetic panels that cover expanded star alleles (*4 through *8).

Can diet or lifestyle compensate for a CYP2C19*8 variant?

Dietary and lifestyle adjustments cannot alter your underlying genetic CYP2C19 enzyme structure. While avoiding certain enzyme inhibitors like omeprazole can prevent further metabolic slowdown, any medication adjustments must be managed directly by your medical provider.

Sources & further reading

Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.

Curious what your genotype is for rs72549307?

Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.

Get my report — $29